Aurora BioPharma, Inc. CEO Meets with Investors at 2015 New England Venture Summit
CAMBRIDGE, MA - December 9, 2015 - The CEO of Aurora BioPharma, Inc., Robert Brooks, will attend the New England Venture Summit taking place December 9th, 2015 at the Hilton Boston Dedham. The illustrious industry gathering is presented by youngStartup Ventures and connects top tier VCs, corporate VCs, venture capitalists, angel investors, university researchers, and incubators.
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. The Company is one of a handful of companies with Chimeric Antigen Receptor T-cell therapy (CAR T) in clinical trials in solid tumor, and pre-clinical trials in liquid and solid tumor. The Company is planning its CAR T cell agent AU-105, a randomized multisite Phase II Glioblastoma trial, and a Phase I intracranial injection trial. Aurora's team is comprised of experienced research scientists and business professionals with successful track records in the industry.
About youngStartup's Venture Summits
The youngStartup's Venture Summits are events where company executives congregate to discuss investment opportunities with investment bankers, investors, advisors, and other industry professionals. The events play host to important panel discussions on the latest scientific discoveries and serve as an opportunity to forge the connections necessary to succeed.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: 617-674-7718 - Fax: 617-674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: 305-371-2301 - Fax: 305-371-2301
email@example.com - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy -
Source: Aurora BioPharma, Inc.